Dr. Lingyan Zhou | Cell Death Pathway | Best Researcher Award

Dr. Lingyan Zhou , Shandong Provincial Hospital Affiliated to Shandong First Medical University , China

Dr. Lingyan Zhou is a dedicated neuroscientist and clinician specializing in the pathogenesis of neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease. Currently serving in the Department of Neurology at Shandong Provincial Hospital affiliated with Shandong First Medical University, Dr. Zhou holds a doctorate and has made notable contributions to neurodegeneration research through high-impact publications and cutting-edge studies. Her work focuses on molecular mechanisms such as protein aggregation, homocysteinylation, and neuroprotection, with particular attention to α-synuclein and DJ-1. Dr. Zhou has co-authored more than 15 peer-reviewed articles in top-tier journals like Nature Communications, Science Advances, and Aging Cell, earning recognition for her insights into disease-modifying pathways. A researcher with a strong translational focus, she bridges the gap between bench and bedside, aiming to develop therapeutic strategies that can mitigate or reverse neurodegenerative processes. Her commitment to science and patient-centered research makes her a strong candidate for the Best Researcher Award.

Publication Profile:

Orcid

✅ Strengths for the Award:

1. Strong Publication Record in High-Impact Journals
   Dr. Zhou has consistently published in top-tier journals such as Nature Communications, Science Advances, Aging Cell, and Movement Disorders, reflecting the significance and innovation of her work. Many of these are Q1 journals with high impact factors.

2. Focused Research on Neurodegeneration
   Her core focus on the molecular basis of Alzheimer’s and Parkinson’s disease, especially novel mechanisms like N-homocysteinylation, STAT1-PARP1, and microRNA signaling, demonstrates depth and relevance to global health priorities.

3. Translational Impact
   Her research bridges basic science and clinical application, particularly through studies on neuroprotection, early disease biomarkers, and potential therapeutic targets.

4. Early Career Excellence
   Despite being in the early stages of her career, Dr. Zhou has already authored or co-authored over 17 peer-reviewed publications, many as first or corresponding author, which is exceptional at this stage.

5. Multidisciplinary Collaborations
   Dr. Zhou’s collaborations with experts across genetics, immunology, bioinformatics, and neurology highlight her integrative approach to complex diseases.

6. International Visibility
   Multiple articles are indexed in PubMed, Crossref, and DOIs, showing her research has international academic presence and reach.

⚠️ Areas for Improvement:

1. Greater International Exposure
   While her publication record is strong, further participation in international neuroscience conferences, workshops, or global consortia would enhance visibility and foster leadership roles.

2. Grant Leadership and Independent Funding
   As she progresses, securing independent research funding and leading grant-funded projects will further demonstrate research independence and strengthen her candidacy for top-tier awards.

3. Mentorship and Teaching Roles
   Involvement in structured mentorship or supervision of Ph.D./postdoctoral researchers could be better highlighted to show contributions to research training and capacity building.

4. Innovation Translation Pathway
   Filing patents or initiating translational collaborations with biotech/pharma could underline the practical applicability of her findings.

🎓 Education:

Dr. Lingyan Zhou received her doctorate from Wuhan University, one of China’s leading research institutions, between September 2020 and June 2023. During her Ph.D. training, she developed expertise in molecular neuroscience and translational medicine, with a specific focus on the pathological mechanisms underlying Parkinson’s and Alzheimer’s diseases. Her research explored cellular stress pathways, protein misfolding, and epigenetic regulation in neurodegeneration, leading to multiple first-author publications in high-impact journals. Her academic background provided a solid foundation in experimental techniques such as immunohistochemistry, gene expression analysis, and in vivo disease modeling. The interdisciplinary approach at Wuhan University enriched her understanding of both clinical neurology and basic neuroscience. This rigorous academic training has equipped Dr. Zhou with the analytical and research skills necessary for advancing innovation in neurodegenerative disease treatment.

🧪 Experience:

Since July 2023, Dr. Lingyan Zhou has been serving in the Department of Neurology at Shandong Provincial Hospital affiliated with Shandong First Medical University, where she engages in both clinical practice and translational neuroscience research. Prior to that, she completed her doctoral studies at Wuhan University, where she developed a deep interest in the role of homocysteine metabolism and genetic regulation in Parkinson’s disease. Over her career, she has collaborated with multidisciplinary teams to investigate molecular and cellular mechanisms of neurodegeneration and published extensively in internationally recognized journals. Her current position allows her to continue high-impact research while mentoring junior colleagues and participating in multi-center studies. Her combined experience in basic research, clinical neurology, and academic collaboration has established her as a key contributor in the field of neurodegenerative diseases, positioning her well for leadership roles and research recognition such as the Best Researcher Award.

🧠 Research Focus:

Dr. Lingyan Zhou’s research is centered on understanding the molecular and cellular mechanisms that drive neurodegenerative diseases, with an emphasis on Alzheimer’s and Parkinson’s disease. Her work has shed light on pathological protein modifications, such as N-homocysteinylation of α-synuclein and DJ-1, which contribute to protein aggregation and neurotoxicity. Additionally, she investigates the neuroprotective roles of vitamins, retinoic acid, and microRNAs in slowing disease progression. Dr. Zhou is also exploring how infectious diseases like SARS-CoV-2 may trigger or exacerbate neurological disorders, expanding the understanding of systemic factors in brain health. Her studies leverage both in vitro and in vivo models to unravel pathways involving STAT1, PARP1, and Notch signaling. By identifying potential therapeutic targets and biomarkers, her research aims to guide the development of novel treatment strategies that could improve outcomes for patients suffering from movement disorders and cognitive decline.

📚 Publications Top Notes:

1. 🧪 N-homocysteinylation of alpha-synuclein promotes its aggregation and neurotoxicity – Aging Cell (2022)

2. 🧠 Association of vitamin B2 intake with cognitive performance in older adults: a cross-sectional study – J Transl Med (2023)

3. 🧬 Homocysteine and Parkinson’s disease – CNS Neurosci Ther (2023)

4. 🧴 Retinoic Acid Prevents alpha-Synuclein Preformed Fibrils-Induced Toxicity via Inhibiting STAT1-PARP1 Signaling – Mol Neurobiol (2023)

5. 🧫 N-homocysteinylation of DJ-1 promotes neurodegeneration in Parkinson’s disease – Aging Cell (2024)

6. 🦠 SARS-CoV-2: Underestimated damage to nervous system – Travel Med Infect Dis (2020)

7. 💊 Potential therapeutic drugs for ischemic stroke based on bioinformatics analysis – Int J Neurosci (2019)

8. 🧬 PTPN22 Gene Polymorphisms and Stroke Susceptibility – Dis Markers (2019)

9. 🧪 IL-18 Gene Polymorphisms and Risk of Ischemic Stroke: A Meta-analysis – Neuroreport (2019)

10. 🚬 Aromatic hydrocarbon receptor links smoking and rheumatoid arthritis – Clin Exp Rheumatol (2020)

🧾 Conclusion:

Dr. Lingyan Zhou demonstrates an exceptional trajectory for a young neuroscience researcher. Her deep and original contributions to unraveling molecular mechanisms in neurodegeneration, particularly Parkinson’s and Alzheimer’s disease, make her highly deserving of recognition. The breadth and quality of her publication record—combined with her translational outlook—signal a rising star in neurodegenerative disease research.